Skip to Content

SHIELD-2

Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)

Patient Information

This study will evaluate the efficacy and safety of Azimilide on the incidence of cardiovascular hospitalizations, cardiovascular emergency department visits or cardiovascular death in patients with Implantable Cardioverter Defibrillators (ICDs).

More details at: http://clinicaltrials.gov/ct2/show/NCT01464476

Study Number
NCT01464476

Clinical Trial Categories

  • Electrophysiology Trials

Also in this Section